Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

ounced the initiation of a Phase 2a clinical study of cysteamine bitartrate in NASH patients, in collaboration with UCSD. In November, 2008 Raptor announced a collaboration with Centre Hospitalier Universitaire d'Angers, in France, to study DR Cysteamine in Huntington's Disease, a rare, genetic neurological disease.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2") deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that Raptor will be able to fully enroll and complete the clinical trial in cystinosis patients; that data will be available in the third quarter of 2009; that Raptor will start a Phase 3 clinical trial in cystinosis
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... engineering research at the University of Pennsylvania demonstrates ... to nanoscale semiconductors. This represents a promising advance ... circuits that use light rather than electricity. ... Agarwal, postdoctoral fellow Lambert van Vugt and graduate ...
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that it has completed a previously announced ... of approximately $6.5 million. Under the terms ... 1,857,143 units to certain institutional investors for a purchase ...
... ("NeoStem" or the "Company") (NYSE Amex: NBS ... revenues, global research and development capabilities and operations in ... China adult stem cells, and China pharmaceuticals, announced today ... will present at the Proactive Investors One2One Investor Forum ...
Cached Biology Technology:Penn researchers break light-matter coupling strength limit in nanoscale semiconductors 2Penn researchers break light-matter coupling strength limit in nanoscale semiconductors 3PharmAthene Completes $6.5 Million Registered Direct Offering 2PharmAthene Completes $6.5 Million Registered Direct Offering 3NeoStem to Present at Two Investor Events This Month 2NeoStem to Present at Two Investor Events This Month 3NeoStem to Present at Two Investor Events This Month 4
(Date:10/22/2014)... 2014 The Nano-Bio Manufacturing Consortium (NBMC), an ... Laboratory (AFRL), has chosen a project proposed by the ... of Arizona College of Medicine – Tucson ... goal is to assess different sweat collection methods and ... sweat under a variety of human-body conditions, the results ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2
... present its fourth annual Regional Policy Award to Karen Hixon ... Society,s 96th Annual Meeting on Sunday August 7 in Austin, ... who has an outstanding record of informing political decision-making with ... Parks and Wildlife Commission by Governor Rick Perry in 2007 ...
... network of researchers will evaluate potential harmful effects ... birth outcomes, the cardiorespiratory system, and behavior and ... partnerships, under the leadership of NIH,s National Institute ... to evaluate the level of potentially harmful contaminants ...
... GALVESTON, Texas In an effort to determine the ... BP oil spill,the National Institute of Environmental Health Sciences ... consortium of university researchers and Gulf Coast community groups ... Galveston to examine the safety of Gulf seafood and ...
Cached Biology News:Texas Parks Wildlife Commission member Karen Hixon to receive ESA's 2011 Regional Policy Award 2NIH-funded research network to explore oil spill health effects 2UTMB-led researchers awarded $7.8 million for Gulf spill study 2UTMB-led researchers awarded $7.8 million for Gulf spill study 3
...
Pronase Reagent...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: